Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer

Current Medical Research and Opinion

Volumn 22, Issue 4, 2006, Pages 649-655

  Berges, R ^a,c   Bello, U ^b  

^a PAN Klinik am Neumarkt   (Germany)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c NONE   (Germany)

Author keywords

Castration levels; Eligard; Leuprorelin acetate; New formulation; Prostate cancer; Slow release

Indexed keywords

ANDROGEN; ANTIANDROGEN; BUSERELIN; DIETHYLSTILBESTROL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MICROSPHERE; TESTOSTERONE; TRIPTORELIN;

ADVANCED CANCER; AREA UNDER THE CURVE; CASTRATION; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; FATIGUE; GYNECOMASTIA; HORMONAL THERAPY; HORMONE DEPENDENCE; HOT FLUSH; HUMAN; IMPLANT; INJECTION SITE DISCOMFORT; LIBIDO DISORDER; MALAISE; ORCHIECTOMY; PROSTATE; PROSTATE CANCER; ROOM TEMPERATURE; SHORT SURVEY; TESTIS ATROPHY; TUMOR FLARE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DRUG TOXICITY; HUMANS; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 33646248080     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X96425     Document Type: Short Survey

References (28)

1. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-8
2. Aus G, Abbou CC, Heidenreich A, et al. Guidelines on prostate cancer European Association of Urology. Update February 2003
3. Schalken J. Androgen receptor mediated growth of prostate cancer. Eur Urol Suppl 2005;4(5):4-11
4. van Leenders GJ, Schalken JA. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. Br J Urol 2001;88(Suppl 2):35-42
5. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65
6. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-70
7. Schulman CC. LHRH agonists in prostate cancer: optimising testosterone control with Eligard. Eur Urol Suppl 2005;4(5):1-3
8. Oefelein MG, Resnick MI. Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 2003;62:207-13
9. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021-4
10. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchidectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-8
11. Rohl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992;26:11-4
12. Lin BJ, Chen KK, Chen MT, Chang LS. The time for serum testosterone to reach castrate level after bilateral orchidectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 1994;43:834-7
13. Zlotta A, Debruyne FMJ. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol Suppl 2005;4(8):37-41
14. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH] agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005;4(5):14-19
15. Andriole GL, Humphrey P, Ray P, et al., Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172:915-9
16. Geller J, Albert JD, Nacsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchidectomy or oestrogen therapy. J Urol 1984;132:693-6
17. Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostatic cancer. In: De Vita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: Lippincott; 1995. p. 193-217
18. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000;164:3-9
19. Tombal B, Berges R. How good [sic] do current LHRH agonists control testosterone? Can this be improved with Eligard. Eur Urol Suppl 2005;4(8):30-6
20. Zinner N, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004;64:1177-81
21. The Leuprolide Study Group. Leuprolide versus diethyl-stilbestrol for metastatic prostate cancer. New Engl J Med 1984;311:1281-6
22. Atrix Laboratories, Inc. Doc No. 1375A.000. Stability report for end of shelf-life for one-month leuprolide acetate 7.5 mg - Stability Lots 1268 and 1270. March 2003, data on file
23. Atrix Laboratories, Inc. Doc No. 1377A.000 Stability report for European end of shelf-life for three-month leuprolide acetate 22.5 mg - Stability Lots 1272 and 1274. March 2003, data on file
24. Cox C. Treatment options gel with innovative drug delivery systems. Drug Delivery Technol 2003;3:8
25. Perez-Marreno R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5:447-57
26. Perez-Marreno R, Chu FM, Gleason D, et al. A six-month open label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902-14
27. Chu FM, Jayson M, Dineen MK, et al. A clinical study of 22.5 mg LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168:1199-203
28. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306